IN002.5.1

IN002.5.1 is a broad-spectrum SARS-CoV-2 mRNA vaccine developed using proprietary lipid nanoparticle (LNP) technology by Innorna, a clinical-stage biotech company specializing in novel mRNA vaccines and therapeutics[1]. The vaccine encodes mutant epitopes of the spike protein shared among various COVID-19 variants, aiming to elicit effective immunity against multiple SARS-CoV-2 strains, including Delta and Omicron[7]. Clinical data from Phase I trials demonstrated an excellent safety and tolerance profile with strong neutralizing antibody titers and favorable Th-1 dominant T cell activation at 28 days post-administration; no Grade 3 or higher adverse reactions or serious adverse events were reported[1]. The U.S. FDA approved a Phase II clinical trial for IN002.5.1 in April 2024, supporting its further development as part of combined respiratory virus vaccines[1].